Preview

Научно-практическая ревматология

Расширенный поиск

Европейские (EULAR/ERA-EDTA) рекомендации по диагностике и лечению АНЦА-ассоциированных системных васкулитов – 2016

https://doi.org/10.14412/1995-4484-2017-12-16

Полный текст:

Аннотация

В начале 2016 г. международной группой экспертов – членов Европейской антиревматической лиги (EULAR), Европейской ассоциации по изучению болезней почек (ERA-EDTA) и Европейского общества изучения васкулитов (EUVAS) были опубликованы новые рекомендации по диагностике и лечению системных васкулитов (СВ), ассоциированных с антинейтрофильными цитоплазматическими антителами (АНЦА). Эти рекомендации являются важным этапом в развитии концепции АНЦА-СВ и стали результатом систематизированного обобщения современных научных достижений и клинического опыта. Предложенные 15 рекомендаций EULAR/ERA-EDTA освещают широкий круг проблем АНЦА-СВ и должны способствовать совершенствованию диагностики, повышению эффективности терапии и улучшению прогноза этих заболеваний. Целью публикации является общая характеристика основных положений рекомендаций.

Об авторе

Т. В. Бекетова
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия

Москва, Россия 115522 Москва, Каширское шоссе, 34А



Список литературы

1. Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016 Jun 23. pii: annrheumdis- 2016-209133. doi: 10.1136/annrheumdis-2016-209133

2. Aasarod K, Bostad L, Hammerstrom J, et al. Renal histopathology and clinical course in 94 patients with Wegener's granulomatosis. Nephrol Dial Transplant. 2001;16:953-60. doi: 10.1093/ndt/16.5.953

3. Schnabel A, Holl-Ulrich K, Dalhoff K, et al. Efficacy of transbronchial biopsy in pulmonary vaculitides. Eur Respir J. 1997;10:2738-43. doi: 10.1183/09031936.97.10122738

4. Corapi KM, Chen JL, Balk EM, et al. Bleeding complications of native kidney biopsy: a systematic review and meta-analysis. Am J Kidney Dis. 2012;60:62-73. doi: 10.1053/j.ajkd.2012.02.330

5. De Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized rial. Ann Intern Med. 2009;150:670-80. doi: 10.7326/0003-4819-150-10-200905190-00004

6. Guillevin L, Cordier JF, Lhote F, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum. 1997;40:2187- 98. doi: 10.1002/1529-0131(199712)40:12<2187::AIDART12>3.0.CO;2-H

7. Harper L, Morgan MD, Walsh M, et al. Pulse versus daily oral cyclophosphamide for nduction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis. 2012;71:955-60. doi: 10.1136/annrheumdis-2011-200477

8. Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA- associated renal vasculitis. N Engl J Med. 2010;363:211-20. doi: 10.1056/NEJMoa0909169

9. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA- associated vasculitis. N Engl J Med. 2010;363:221-32. doi: 10.1056/NEJMoa0909905

10. De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52:2461-9. doi: 10.1002/art.21142

11. Langford CA, Talar-Williams C, Sneller MC. Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis. Long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum. 2000;43:1836-40. doi: 10.1002/1529- 0131(200008)43: 8<1836: :AIDANR20>3.0.CO;2-R

12. Metzler C, Hellmich B, Gause A, et al. Churg Strauss syndrome – successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment. Clin Exp Rheumatol. 2004;22(6 Suppl.):S-52-61.

13. Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: A data-driven review. Arthritis Rheum. 2010;62:9-21. doi: 10.1002/art.25061

14. Miloslavsky EM, Specks U, Merkel PA, et al. Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids. Arthritis Rheum. 2015;67:1629-36. doi: 10.1002/art.39104

15. Klemmer PJ, Chalermskulrat W, Reif MS, et al. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with Small-Vessel vasculitis. Am J Kidney Dis. 2003;42:1149-53.doi: 10.1053/j.ajkd.2003.08.015

16. Levy JB, Hammad T, Coulthart A, et al. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int. 2004;66:1535-40. doi: 10.1111/j.1523-1755.2004.00917.x

17. Metzler C, Miehle N, Manger K, et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford). 2007;46:1087-91. doi: 10.1093/rheumatology/kem029

18. Stegeman CA, Tervaert JWC, de Jong PE, et al. Trimethoprimsulfamethoxazole (Co- trimoxazole) for the prevention of relapses of Wegener's granulomatosis. N Engl J Med. 1996;335:16-20. doi: 10.1056/NEJM199607043350103

19. Springer J, Nutter B, Langford CA, et al. Granulomatosis with polyangiitis (Wegener's): impact of maintenance therapy duration. Medicine (Baltimore). 2014;93:82-90. doi: 10.1097/MD.0000000000000020

20. Walsh M, Merkel PA, Mahr A, et al. Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. Arthritis Care Res (Hoboken). 2010;62:1166-73. doi: 10.1002/acr.20176

21. Pagnoux C, Hogan SL, Chin H, et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibodyassociated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum. 2008;58:2908-18. doi: 10.1002/art.23800

22. Hellmich B, Flossmann O, Gross WL, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibodyassociated vasculitis. Ann Rheum Dis. 2007;66:605-17. doi: 10.1136/ard.2006.062711

23. Holle JU, Voigt C, Both M, et al. Orbital masses in granulomatosis with polyangiitis are associated with a refractory course and a high burden of local damage. Rheumatology (Oxford). 2013;52:875-82. doi: 10.1093/rheumatology/kes382

24. Pullerits R, Ljevak M, Vikgren J, et al. Off-trial evaluation of the B cell-targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)- associated vasculitis: long-term follow-up from a single centre. Scand J Immunol. 2012;76:411-20. doi: 10.1111/j.1365-3083.2012.02747.x

25. Seror R, Pagnoux C, Ruivard M, et al. Treatment strategies and outcome of induction- refractory Wegener's granulomatosis or microscopic polyangiitis: analysis of 32 patients with first-line induction-refractory disease in the WEGENT trial. Ann Rheum Dis. 2010;69:2125-30. doi: 10.1136/ard.2010.131953

26. Fortin PM, Tejani AM, Bassett K, et al. Intravenous immunoglobulin as adjuvant therapy for Wegener's granulomatosis. Cochrane Database Syst Rev. 2013;1:CD007057. doi: 10.1002/14651858.CD007057.pub3

27. Тomasson G, Grayson PC, Mahr AD, et al. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis – a meta-analysis. Rheumatology (Oxford). 2012;51:100-9. doi: 10.1093/rheumatology/ker280

28. Finkielman JD, Lee AS, Hummel AM, et al. ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis. Am J Med. 2007;120:643.e9-14. doi: 10.1016/j.amjmed.2006.08.016

29. Mukhtyar C, Lee R, Brown D, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2009;68:1827-32. doi: 10.1136/ard.2008.101279

30. Exley AR, Bacon PA, Luqmani RA, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum. 1997;40:371-80. doi: 10.1002/art.1780400222

31. Guillevin L, Pagnoux C, Seror R, et al. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine. 2011;90:19-27. doi: 10.1097/MD.0b013e318205a4c6

32. De Groot K, Gross WL, Herlyn K, Reinhold-Keller E. Development and validation of a disease extent index for Wegener's granulomatosis. Clin Nephrol. 2001;55(1):31-8.

33. Alberici F, Smith RM, Jones RB, et al. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Rheumatology (Oxford). 2015;54:1153-60. doi: 10.1093/rheumatology/keu452

34. Suppiah R, Judge A, Batra R, et al. A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. Arthritis Care Res (Hoboken). 2011;63:588-96. doi: 10.1002/acr.20433


Для цитирования:


Бекетова Т.В. Европейские (EULAR/ERA-EDTA) рекомендации по диагностике и лечению АНЦА-ассоциированных системных васкулитов – 2016. Научно-практическая ревматология. 2017;55(1):12-16. https://doi.org/10.14412/1995-4484-2017-12-16

For citation:


Beketova T.V. THE 2016 EUROPEAN (EULAR/ERA-EDTA) RECOMMENDATIONS FOR THE DIAGNOSIS AND MANAGEMENT OF ANCA-ASSOCIATED SYSTEMIC VASCULITIS. Rheumatology Science and Practice. 2017;55(1):12-16. (In Russ.) https://doi.org/10.14412/1995-4484-2017-12-16

Просмотров: 1292


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)